In a study performed with osteosarcoma patients, elevated levels of NRP1 forecasted lower chemotherapeutic response [47], and higher NRP1 plasma levels were established as predictors of bevacizumab efficacy in patients with gastric cancer [51]. The gene discussed is NRP1; the disease is gastric cancer.